Author:
Rao Koya Prabhakara,babu Namburi LAAmara,Koganti Kalyani,Palakeeti Babji,Srinivas Koduri S. V.
Abstract
AbstractThe present application wish to seem at the event of validation of bio analytical method and pharmacokinetic study of selexipag and its related impurities in rat plasma using LC–MS/MS. The optimized method contains gradient elution of selexipag with a flow rate of 1 ml/min and X-Bridge phenyl column (150 × 4.6 mm, 3.5 µ). A buffer of 1 mL formic acid in l liter water and acetonitrile mixture is used as mobile phase. 30 min run time was used for separation of selexipag and its related impurities with Ambrisentan as internal standard and impurity-D as active metabolite. The linearity curves are linear in between the percentages of 10 to 200% of rat plasma and R2 value of each analyte was observed as 0.999. This application denotes all the parameters like precision, accuracy, recovery and stability were got the results within the limit of USFDA guidelines. This method applies effectively for the investigation of pharmacokinetic studies using rat plasma.
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Physics and Astronomy,General Engineering,General Environmental Science,General Materials Science,General Chemical Engineering
Reference26 articles.
1. US FDA (2019) Seeks additional data from Actelion's NDA for Opsumit to treat CTEPH (NDA 204410/S-020). PharmaBiz. Athena information solutions PVT. Ltd, South San Francisco, California, USA
2. Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfmuller P et al (2017) EIf2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation 136(21):2022–2033
3. George MP, Champion HC, Pilewski JM (2011) Lung transplantation for pulmonary hypertension. Pulm Circ 1(2):182–191
4. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M et al (2013) Structure and function of an irreversible agonist-β (2) adrenoceptor complex. Nature 469(7329):236–40
5. De Min A, Matera C, Bock A et al (2017) A new molecular mechanism to engineer protean agonism at a G-protein coupled receptor. Mol Pharm 91(4):348–356
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献